Valuation
- Market cap
- 37,250,000
- Revenue TTM
- $0
- Net income TTM
- $-5,860,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 6,500
- Avg volume
- 16,556
- Day's range
- $3.05 – $3.22
- Shares out
- 11,714,000
- Stochastic %K
- 12%
- Beta
- 4.18
- Analysts
- Strong Sell
- Price target
- $18.50
Company profile
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Nalo...
Show more
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Phone
- 972 3 573 6632
- Website
- https://www.nasuspharma.com
- Address
- Yigal Alon 65, Tel Aviv-Yafo, Israel
Latest news
No headlines yet.
